FytonBio | with Monash Ventures Pre-Seed Fund
FytonBio secured one million dollars in pre-seed funding from Breakthrough Victoria and Monash University to develop antibody therapies for autoimmune diseases using Monash's GREAT platform.
Co-founder and CEO, Fyton Bio
| Role | Organisation | Sources |
|---|---|---|
| Co-founder and CEO | Fyton Bio | Startup Daily, SmartCompany, Breakthrough Victoria (1 Aug 2025), Breakthrough Victoria (1 Aug 2025) |
Stories naming Chuck Silberstein. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
FytonBio secured one million dollars in pre-seed funding from Breakthrough Victoria and Monash University to develop antibody therapies for autoimmune diseases using Monash's GREAT platform.
Two Victorian backers put a combined $2.25 million into three university spinouts pursuing biologics, antibody drugs and delivery devices, launching a new $15 million pre-seed vehicle.
Also @AuManufacturing
Weekly roundup: Breakthrough Victoria and Monash University co-invest $2.25 million across three university healthtech spinouts, while Blackbird backs Hall, which helps businesses win visibility on AI platforms, with $2 million pre-seed.
Also Startup Daily
Breakthrough Victoria and Monash University put joint pre-seed backing into three life-sciences spinouts and launched the $15m Monash Ventures pre-seed fund, part of a $100m platform commercialising Victorian university research.
The investor's site reports a joint pre-seed investment with Monash University totalling $2.25 million across three health startups, and the launch of Monash Ventures' $15 million pre-seed fund for research commercialisation.
Also Breakthrough Victoria·SmartCompany·@AuManufacturing·@AuManufacturing